Publikationen, an denen er mitarbeitet Luis Fernando López Cortés (10)

2022

  1. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial

    Clinical Microbiology and Infection, Vol. 28, Núm. 8, pp. 1151.e9-1151.e16

  2. Incidence Rate and Risk Factors for Anal Squamous Cell Carcinoma in a Cohort of People Living With HIV from 2004 to 2017: Implementation of a Screening Program

    Diseases of the colon and rectum, Vol. 65, Núm. 1, pp. 28-39

2020

  1. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase-or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 1, pp. 200-207

  2. Modulation of monocyte activation and function during direct antiviral agent treatment in patients coinfected with HIV and hepatitis C virus

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 9

  3. Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study

    Journal of the International AIDS Society, Vol. 23, Núm. 9

2019

  1. High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance

    Papillomavirus Research, Vol. 7, pp. 62-66

  2. High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate-to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex with Men in Low-to-Absent Cytological Abnormalities

    Clinical Infectious Diseases, Vol. 69, Núm. 12, pp. 2185-2192

2018

  1. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment

    PLoS ONE, Vol. 13, Núm. 10

  2. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients

    Journal of Infectious Diseases, Vol. 218, Núm. 4, pp. 624-632

  3. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

    PLoS ONE, Vol. 13, Núm. 9